Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 16/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092261 | 0.86 | ADRB3 (0.57) | ADRB3ADRB1ADRB2LMNANFKB1 | |
| SCHEMBL7092794 | 0.86 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7701777 | 0.86 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7145977 | 0.85 | ADRB3 (0.81) | ADRB3ADRB1ADRB2LMNANFKB1 | |
| SCHEMBL7178964 | 0.85 | ADRB3 (0.79) | ADRB3ADRB1ADRB2LMNANFKB1 | |
| SCHEMBL7164357 | 0.85 | ADRB3 (0.85) | ADRB3ADRB1ADRB2LMNANFKB1 | |
| SCHEMBL7096112 | 0.85 | ADRB3 (0.85) | ADRB3ADRB1ADRB2LMNANFKB1 | |
| SCHEMBL7094547 | 0.85 | ADRB3 (1.00) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL5166476 | 0.84 | ADRB3 (0.81) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7094593 | 0.84 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.